26 results
Common Causes of the Different Categories of Dizziness #Diagnosis #PrimaryCare #EM #IM #Differential #Dizziness #Vertigo #Disequilibrium
#PrimaryCare #EM ... #IM #Differential ... Lightheadedness #Table ... #NEJM
Differential Diagnosis of Jaundice, Presentation Pattern #Diagnosis #EM #IM #GI #Jaundice #Pattern #LFTs #Workup #Table #Differential
Pattern #Diagnosis #EM ... #IM #GI #Jaundice ... #LFTs #Workup #Table
Catecholamine Vasopressor Effect Sites and Indications #Pathophys #Management #EM #IM #PCC #Catecholamine #Comparison #Table #Epi #Norepi
Pathophys #Management #EM ... #IM #PCC #Catecholamine ... #Comparison #Table
A good approach when dealing with hypotension at the bedside includes using the following systematic four
Heart Rate 2. ... Diagnosis #Management #EM ... #IM #PCC #Hypotensive
Table of Common Rate Control Agents via AHA/ACC/HRS Guidelines #Management #Pharm #EM #IM #Cardiology #Afib #Common
Table of Common ... Rate Control Agents ... Management #Pharm #EM ... #IM #Cardiology ... #RateControl #Table
Fremanezumab for the Preventive Treatment of Chronic Migraine - Primary and Secondary End Points #EBM #Neuro
Secondary End Points #EBM ... #Neuro #IM #Fremanezumab ... CalcitoninGeneRelatedPeptideAntibody #Results #NEJM ... #NEJM
Stroke Rate by CHADS2 Score (Gage et al., JAMA, 2001) https://www.ncbi.nlm.nih.gov/pubmed/?term=11401607 #EBM #EM #IM #Cardiology #CHADS2
Stroke Rate by CHADS2 ... term=11401607 #EBM ... #EM #IM #Cardiology
Fremanezumab for the Preventive Treatment of Chronic Migraine - Adverse Events in the Safety Population, According
to Trial Group #EBM ... #Neuro #IM #Fremanezumab ... AdverseEvents #NEJM ... #NEJM
Fremanezumab for the Preventive Treatment of Chronic Migraine - Primary and Secondary End Points #EBM #Neuro
Secondary End Points #EBM ... #Neuro #IM #Fremanezumab ... CalcitoninGeneRelatedPeptideAntibody #NEJM
Features of Noninferiority Studies #EBM #Noninferiority #Features #Table #NEJM
Noninferiority Studies #EBM ... Noninferiority #Features #Table ... #NEJM